Product Information
BUPROPION HCL XL 300 MG TABLET is a generic product labeled by TWi Pharmaceuticals, Inc., priced at $0.1115 per EA under NDC 24979010207. Its NADAC has been published 406 times since Sep 26, 2018.
FDA first approved this application on Nov 3, 2017.
Strength
300 mg/1
Manufacturer
TWi Pharmaceuticals, Inc.NDC
24979010207
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
6/17/2026
Active Ingredients
BUPROPION HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA210081FDA Approved
11/3/2017
On Market Since
8/30/2018
Pharmacological Classes
Price Statistics
The NADAC for BUPROPION HCL XL 300 MG TABLET has been published 406 times since Sep 26, 2018, and over the history we have for it it has declined 72.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1115 per EA |
|---|---|
| All-time high | $0.4702 (Sep 11, 2019) |
| All-time low | $0.1033 (Feb 18, 2026) |
| 52-week high | $0.1461 |
| 52-week low | $0.1033 |
| Median price | $0.1795 |
| Average price | $0.2108 |
| Largest weekly change | -33.9% (Sep 18, 2019) |
| Weeks tracked | 406 |
| Tracking since | Sep 26, 2018 |
1W
N/A
1M
N/A
3M
N/A
6M
+3.9%
1Y
-23.7%
3Y
-30.9%
5Y
-43.3%
All
-72.9%
Last surveyed Jul 1, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 9 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 10% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
TWi Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
bupropion hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminoketone class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUPROPION HCL XL 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for BUPROPION HCL XL 300 MG TABLET, manufactured by TWi Pharmaceuticals, Inc., is $0.1115 per EA (NDC 24979010207), effective Jul 1, 2026.
How has the price of BUPROPION HCL XL 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for BUPROPION HCL XL 300 MG TABLET has declined 72.9%. It has been tracked across 406 weekly CMS publications since Sep 26, 2018.
What are the highest and lowest recorded NADAC prices for BUPROPION HCL XL 300 MG TABLET?
Since Sep 26, 2018, the NADAC for BUPROPION HCL XL 300 MG TABLET has ranged from a low of $0.1033 (Feb 18, 2026) to a high of $0.4702 (Sep 11, 2019), with a median of $0.1795 per EA.
Are there cheaper alternatives to BUPROPION HCL XL 300 MG TABLET?
Yes. 9 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, BUPROPION HCL XL 300 MG TABLET, is $0.1004 per EA — about 10% below BUPROPION HCL XL 300 MG TABLET.
Who manufactures BUPROPION HCL XL 300 MG TABLET?
BUPROPION HCL XL 300 MG TABLET (NDC 24979010207) is labeled by TWi Pharmaceuticals, Inc., and CMS classifies it as a generic product.